Sezary Syndrome
📧 Sign up to get email alerts when something new happens for Sezary Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Aclarubicin in combination with cyclophosphamide, vincristine, and prednisone (CAOP) in patients with …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers [Phase 2]
This Phase 2 clinical trial update evaluates the combination of talimogene laherparepvec (T-VEC) and nivolumab for patients with refractory …
-
EMA approval · 2026-04-08EMA Authorised: Poteligeo (mogamulizumab) — Kyowa Kirin Holdings B.V.
The EMA authorised Poteligeo (mogamulizumab) for Sezary Syndrome and Mycosis Fungoides. The designation includes orphan medicine status and …
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL [Phase 1]
Phase 1 study of CAR-T cells targeting CD30 and CCR4 for relapsed/refractory CD30+ Hodgkin lymphoma and cutaneous T-cell lymphoma, with the …
-
CLINICAL_TRIALS trial_result · 2025-10-16Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment [Phase 1, Phase 2]
The NCI-announced Phase 1/2 trial testing magrolimab added to mogamulizumab for recurrent or refractory Mycosis Fungoides/Sezary Syndrome wa…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-09-18Clinical Trial Update: Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating durvalumab with or without lenalidomide in patients with relapsed or refractory cutaneous or periph…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides [Phase 2]
Phase 2 trial evaluating pembrolizumab in patients with stage IB-IV mycosis fungoides and Sezary syndrome has completed, with results posted…
-
CLINICAL_TRIALS research · 2025-05-21Clinical Trial Update: A Registry for People With T-cell Lymphoma
A registry study at Memorial Sloan Kettering Cancer Center to enroll people with various T-cell and NK-cell lymphomas; the trial is currentl…
-
CLINICAL_TRIALS research · 2024-12-09Clinical Trial Update: A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) [Phase 2]
A Phase 2 clinical trial evaluating pembrolizumab in combination with radiotherapy for relapsed, refractory cutaneous T-cell lymphoma, speci…
-
CLINICAL_TRIALS research · 2024-11-08Clinical Trial Update: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma [Phase 2]
A Phase 2 clinical trial of IPH4102 (lacutamab) alone or in combination with chemotherapy is evaluating advanced T-cell lymphomas, including…
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides [Phase 1, Phase 2]
Phase 1/2 study of mogamulizumab in combination with extracorporeal photopheresis for Sezary syndrome and mycosis fungoides was terminated.
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab [Phase 2]
Phase 2 trial evaluating letermovir for prevention of cytomegalovirus reactivation in patients with hematologic malignancies treated with al…
-
FDA approval · 2024-03-06FDA Approved: BEXAROTENE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for bexarotene from Mylan Pharmaceuticals Inc., marking regulatory approval of the supplemental subm…
-
CLINICAL_TRIALS trial_result · 2023-05-11Clinical Trial Update: Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma [Phase 2]
Phase 2 clinical trial update for non-myeloablative allogeneic transplantation using TLI and ATG in patients with cutaneous T-cell lymphoma …
-
CLINICAL_TRIALS trial_result · 2022-09-13Clinical Trial Update: Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies [Phase 1]
Phase 1 trial evaluating interleukin-15 in combination with avelumab in relapsed/refractory mature T-cell malignancies completed; results po…
-
CLINICAL_TRIALS trial_result · 2021-12-14Clinical Trial Update: Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome [Phase 1]
Phase I trial evaluating recombinant human IL-15 in combination with mogamulizumab for refractory/relapsed adult T-cell leukemia/lymphoma an…
-
CLINICAL_TRIALS trial_result · 2020-02-24Clinical Trial Update: Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluated Campath-1H–mediated stem cell transplant therapy for advanced Mycosis Fungoides and Sezary Syndrome; th…
-
CLINICAL_TRIALS trial_result · 2019-08-29Clinical Trial Update: Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma [Phase 1]
A Phase 1 dose-escalation study evaluating carfilzomib with and without romidepsin in cutaneous T-cell lymphoma (CTCL) was terminated with r…
-
CLINICAL_TRIALS trial_result · 2019-05-16Clinical Trial Update: Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial assessing Silicon Phthalocyanine 4 with photodynamic therapy in recurrent cutaneous T-cell lymphoma including mycosis fungoide…
-
CLINICAL_TRIALS trial_result · 2019-02-05Clinical Trial Update: Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome [Phase 2]
Phase 2 trial of pembrolizumab in relapsed or refractory mycosis fungoides or Sezary syndrome completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2017-04-05Clinical Trial Update: Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level [Phase 2]
Phase 2 trial results of brentuximab vedotin (SGN-35) in patients with mycosis fungoides/cutaneous T-cell lymphoma with variable CD30 expres…
-
CLINICAL_TRIALS trial_result · 2016-11-29Clinical Trial Update: A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) [Phase 2]
Phase 2 trial of A-dmDT390-bisFv(UCHT1) immunotoxin for cutaneous T-cell lymphoma (CTCL) has completed, with results from the study summariz…
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL [Phase 2]
A Phase 2 trial investigating a combination of bexarotene and rosiglitazone for cutaneous T-cell lymphoma has been completed, with results p…
-
FDA approval · 2015-09-14FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)
The FDA approved a supplemental application for TARGRETIN (bexarotene) submitted by Bausch Health US, LLC.
-
CLINICAL_TRIALS trial_result · 2015-03-23Clinical Trial Update: O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial assessed the combination of O6-Benzylguanine with topical Carmustine in patients with early-stage cutaneous T-cell lymphom…